Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov 22:15:665-669.
doi: 10.2147/IMCRJ.S384356. eCollection 2022.

Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis

Adrian T Babel  1   2 , Eric K Chin  3   4 , David R P Almeida  2
Affiliations
Case Reports

Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis

Adrian T Babel et al. Int Med Case Rep J. .

Abstract

Purpose: Our case emphasizes the utility of long-acting intravitreal fluocinolone implants (YUTIQ) for managing recalcitrant forms of non-infectious posterior uveitis, NIPU.

Patient: We present a case of bilateral NIPU refractory to topical corticosteroids and intravitreal triamcinolone and dexamethasone.

Results: Management with bilateral YUTIQ improved local ocular inflammatory control with improved vision and anatomical outcomes.

Conclusion: NIPU can develop into recurrent forms resistant to short-acting therapeutics. Long-acting efficacy with YUTIQ emphasizes the need to recognize such refractory NIPU cases.

Keywords: NIU; fluocinolone acetonide implant; non-infectious uveitis.

PubMed Disclaimer

Conflict of interest statement

Dr Eric K Chin was involved in research and clinical trials for Opthea, Genentech, Novartis, Iveric, Chendgu Kanghong Biosciences, Kodiak Sciences, and Bayer, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Topical corticosteroid drops OU and previous intravitreal triamcinolone OS, widefield fluorescein angiography (Optos) and optical coherence tomography. Bright green line indicates section of image provided and green arrow has no significance.
Figure 2
Figure 2
Persistent inflammation 6 weeks after Ozudex OD and 8 weeks after Ozurdex OS, widefield fluorescein angiography (Optos) and optical coherence tomography. Bright green line indicates section of image provided and green arrow has no significance.
Figure 3
Figure 3
Improved macular edema 3 months after YUTIQ OD and 1 month after YUTIQ OS, widefield fluorescein angiography (Optos) and optical coherence tomography. Bright green line indicates section of image provided and green arrow has no significance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Takeuchi M, Mizuki N, Ohno S. Pathogenesis of non-infectious uveitis elucidated by recent genetic findings. Front Immunol. 2021;12:640473. doi:10.3389/fimmu.2021.640473 - DOI - PMC - PubMed
    1. Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761–1777. doi:10.2147/OPTH.S180580 - DOI - PMC - PubMed
    1. Huang XF, Brown MA. Progress in the genetics of uveitis. Genes Immun. 2022;23(2):57–65. doi:10.1038/s41435-022-00168-6 - DOI - PMC - PubMed
    1. Kempen JH, Altaweel MM; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122(10):1967–1975. doi:10.1016/j.ophtha.2015.06.042 - DOI - PMC - PubMed
    1. Kuppermann BD, Zacharias LC, Kenney MC. Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:116–141. - PMC - PubMed

Publication types